CRISPR Explained: The future of Genetic Engineering

| September 29, 2019

article image
CRISPR or clustered regularly inter-spaced short palindromic repeats has become a pretty big deal in the world of biotechnology. In this video we will take a look at the very basics of CRISPR and a couple of examples of its applications so that we can build a base understanding of the concepts of this form of biotechnology which can revolutionize gene therapy and genomics.

Spotlight

Bio-XCell Biotechnology Park

Bio-XCell a biotechnology park & ecosystem dedicated to healthcare and industrial biotechnology developed by Malaysian Bio-XCell, is a joint venture company formed between Malaysia Biotechnology Corp and property developer UEM Land in 2009

OTHER ARTICLES

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 13, 2020

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 13, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | April 13, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Spotlight

Bio-XCell Biotechnology Park

Bio-XCell a biotechnology park & ecosystem dedicated to healthcare and industrial biotechnology developed by Malaysian Bio-XCell, is a joint venture company formed between Malaysia Biotechnology Corp and property developer UEM Land in 2009

Events